Vasopressin Receptor

Signaling Pathway

Vasopressin Receptor Signaling Pathway

Vasopressin Receptor Products

  • All (5)
  • Vasopressin Receptor Antagonists (5)
  • New Vasopressin Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
J Mol Cell Biol, 2020, 12(8):644-653
Am J Physiol Renal Physiol, 2015, 309(5):F474-83
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Cell Res, 2022, 1-17
Antimicrob Agents Chemother, 2017, AAC.01674-17
Sci Rep, 2017, 7(1):12881
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
J Mol Cell Biol, 2020, 12(8):644-653
Am J Physiol Renal Physiol, 2015, 309(5):F474-83
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Cell Res, 2022, 1-17
Antimicrob Agents Chemother, 2017, AAC.01674-17
Sci Rep, 2017, 7(1):12881
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.

Choose Selective Vasopressin Receptor Inhibitors

Tags: Vasopressin Receptor inhibitor|Vasopressin Receptor agonist|Vasopressin Receptor activator|Vasopressin Receptor inducer|Vasopressin Receptor antagonist|Vasopressin Receptor signaling pathway|Vasopressin Receptor assay kit